June 2015—Oxford Immunotec announced the availability in the United States of a test that measures the strength of a patient’s cellular immune response to cytomegalovirus. The T-Spot.CMV test is available as a laboratory-developed test from the company’s CLIA-certified and CAP-accredited service laboratory.
T cell immunity against CMV is a factor in controlling viral latency and susceptibility to CMV disease. The T-Spot.CMV test measures the strength of T cell responses to CMV-specific antigens and has the potential to assist clinicians with monitoring antiviral prophylaxis and evaluating patients at risk from CMV disease. The test builds on the company’s capabilities in T cell measurement technology and is the first in a series of planned new products intended to help transplant patients and physicians manage immune regulated conditions.
The test, which is pending approval in California, New York, and Florida, will be performed at Oxford Diagnostic Laboratories in Memphis, Tenn., where validation was performed; test results will be available to customers within two days of receipt of a whole blood sample.
Oxford Immunotec, 508-481-4648